skip navigation

Skip Nav

HIV/AIDS Clinical Trials

Clinical Trial Search Results

184 studies were found about ( atazanavir OR Reyataz )

Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

Condition: HIV; HIV Infections

NCT ID: NCT01108510

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Condition: HIV Infections; Acquired Immunodeficiency Syndrome

NCT ID: NCT00896051

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV; HIV Infections

NCT ID: NCT01106586

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women (WAVES)

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01705574

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression

Condition: Human Immunodeficiency Virus (HIV) Infections

NCT ID: NCT00337467

Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients

Condition: HIV Infection; HIV Infections

NCT ID: NCT00943540

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Condition: HIV; HIV Infections; Acquired Immunodeficiency Syndrome

NCT ID: NCT01967940

Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

Condition: Pediatric HIV; HIV Infections

NCT ID: NCT00940771

ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir

Condition: HIV

NCT ID: NCT02102048

Pharmacokinetics, Safety, and Efficacy of Cobicistat-boosted Atazanavir or Cobicistat-boosted Darunavir in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects

Condition: Acquired Immune Deficiency Syndrome (AIDS); HIV Infections

NCT ID: NCT02016924

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

Condition: HIV Infections

NCT ID: NCT00006604

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

Condition: Infection, Human Immunodeficiency Virus I; HIV Infection

NCT ID: NCT00440947

Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

Condition: HIV Infections

NCT ID: NCT00004584

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

Condition: Acquired Immune Deficiency Syndrome; AIDS; Human Immunodeficiency Virus; HIV Infections

NCT ID: NCT00814879

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

Condition: HIV Infection

NCT ID: NCT00420355

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir

Condition: HIV Infection; Osteopenia

NCT ID: NCT01902186

Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects

Condition: HIV; HIV Infections

NCT ID: NCT01815736

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

Condition: HIV Infection; Mitochondrial Dysfunction

NCT ID: NCT01194856

Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study

Condition: HIV Infection

NCT ID: NCT02034838

Effect of Atazanavir on Endothelial Function in HIV-Infected Patients

Condition: HIV Infections; Dyslipidemia

NCT ID: NCT00447070

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

Condition: HIV Infections

NCT ID: NCT00307502

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

Condition: HIV Infection

NCT ID: NCT00326716

ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

Condition: Human Immunodeficiency Virus (HIV)

NCT ID: NCT00335322

Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

Condition: HIV Infections

NCT ID: NCT00002240

Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)

Condition: HIV Infections

NCT ID: NCT00207142

Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients

Condition: HIV Infections

NCT ID: NCT00122577

Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment

Condition: HIV Infections

NCT ID: NCT00544128

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

Condition: HIV Infections

NCT ID: NCT00762892

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

Condition: HIV Infections

NCT ID: NCT00528060

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

Condition: HIV Infections; Hepatitis C

NCT ID: NCT01105611

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

Condition: Human Immunodeficiency Virus Type 1 (HIV-1); HIV Infections

NCT ID: NCT00833482

Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis

Condition: HIV Infections

NCT ID: NCT00385645

Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy

Condition: HIV Infections

NCT ID: NCT00718536

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

Condition: HIV Infection

NCT ID: NCT01389310

Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

Condition: HIV Infections

NCT ID: NCT00389207

Safety and Efficacy of GS-9350-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV-1 Infection

NCT ID: NCT00892437

A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome

Condition: HIV Infections

NCT ID: NCT00312754

RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients

Condition: Chronic Infection With HIV

NCT ID: NCT01829802

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Condition: HIV Infections

NCT ID: NCT00074581

Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents

Condition: HIV Infections

NCT ID: NCT00207948

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

Condition: HIV Infections

NCT ID: NCT00135395

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

Condition: HIV-1 Infection

NCT ID: NCT01803074

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Condition: HIV

NCT ID: NCT01236235

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

Condition: HIV Infections

NCT ID: NCT00035932

Disulfiram Interactions With HIV Medications: Clinical Implications

Condition: HIV Infections; Drug Abuse

NCT ID: NCT00878306

Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients

Condition: HIV Infections

NCT ID: NCT00355719

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

Condition: HIV Infections

NCT ID: NCT00384904

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Condition: Human Immunodeficiency Virus-1

NCT ID: NCT00827112

Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome

Condition: HIV-Associated Lipodystrophy Syndrome

NCT ID: NCT00135356

Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients

Condition: HIV Infections

NCT ID: NCT00411957

Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

Condition: HIV; HIV Infections

NCT ID: NCT01073761

Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl

Condition: HIV Infections

NCT ID: NCT00532168

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01910402

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

Condition: HIV Infections

NCT ID: NCT00120393

Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression

Condition: Human Immunodeficiency Virus

NCT ID: NCT01599364

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

Condition: HIV Infections

NCT ID: NCT00007202

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts

Condition: HIV-1 Infection; Immunosuppression-related Infectious Disease

NCT ID: NCT01928407

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

Condition: HIV

NCT ID: NCT00757783

Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)

Condition: HIV Infections

NCT ID: NCT00122603

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

Condition: HIV Infection

NCT ID: NCT00082394

Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-Term Observational Study

Condition: HIV Infections

NCT ID: NCT00537966

Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment

Condition: HIV Infection

NCT ID: NCT00280969

A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy

Condition: HIV Infections

NCT ID: NCT00067782

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Condition: HIV

NCT ID: NCT00931801

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

Condition: HIV Infections; Tuberculosis

NCT ID: NCT00096850

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

Condition: HIV

NCT ID: NCT01602822

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

Condition: HIV Infections

NCT ID: NCT00272779

The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects

Condition: HIV Infections

NCT ID: NCT00540137

Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir

Condition: Hepatitis C, Chronic; HIV Infection

NCT ID: NCT01818856

Raltegravir and Atazanavir Dosing Strategy Study

Condition: HIV Infection

NCT ID: NCT00874523

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Condition: HIV Infections

NCT ID: NCT00224445

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

Condition: HIV Infections; Lipodystrophy

NCT ID: NCT00426296

"The Once A Day Protease Inhibitor Regimens"

Condition: HIV Infections

NCT ID: NCT00242216

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)

Condition: HIV Infections

NCT ID: NCT01099579

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

Condition: HIV Infections

NCT ID: NCT00028067

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Condition: HIV

NCT ID: NCT01335698

PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

Condition: HIV Infections

NCT ID: NCT00273273

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

Condition: HIV Infections

NCT ID: NCT00552240

Antiretroviral Drug Interaction Study in Volunteers With HIV

Condition: HIV; PCP; Toxoplasmosis

NCT ID: NCT01479361

A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)

Condition: HIV

NCT ID: NCT01445223

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Condition: Human Immunodeficiency Virus-1

NCT ID: NCT01384734

Evaluation of Atazanavir Substitution Intervention (EASI) Study

Condition: HIV Infections

NCT ID: NCT00247845

Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)

Condition: HIV Infections

NCT ID: NCT01159223

Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia

Condition: Hyperlipidemia; HIV Infections

NCT ID: NCT00160329

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

Condition: HIV Infections

NCT ID: NCT00013520

HIV Antiretroviral Drugs and Metabolism

Condition: HIV Infections

NCT ID: NCT00525239

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Condition: Human Immunodeficiency Virus

NCT ID: NCT01180075

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

Condition: HIV Infections

NCT ID: NCT00884793

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Condition: HIV Infections

NCT ID: NCT02116660

Bioequivalence (BE) Study of Individual Atazanavir and Cobicistat Compared to Atazanavir in Fixed Dose Combination With Cobicistat

Condition: Human Immunodeficiency Virus Type 1 (HIV-1)

NCT ID: NCT01837719

Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia

Condition: HIV

NCT ID: NCT01940198

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

Condition: HIV

NCT ID: NCT01232127

Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults

Condition: HIV Infections

NCT ID: NCT00820118

Atazanavir for HIV Infected Individuals: An Early Access Program

Condition: HIV Infections

NCT ID: NCT00046345

Safety Study of Raltegravir in HIV/HCV Co-infected Patients

Condition: HIV; Hepatitis C

NCT ID: NCT01225705

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

Condition: HIV Infection; Hyperlipidemia

NCT ID: NCT00225017

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

Condition: HIV Infections

NCT ID: NCT00118898

ATV/Ritonavir Nevirapine Interaction (USPAC)

Condition: HIV Infections

NCT ID: NCT00162149

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

Condition: HIV Infections

NCT ID: NCT00551018

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Condition: HIV

NCT ID: NCT01605084

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa

Condition: HIV; Impaired Cognition

NCT ID: NCT01367236

The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception

Condition: Pregnancy; HIV; AIDS

NCT ID: NCT01667978

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

Condition: HIV Infected

NCT ID: NCT01394133

Safety Sudy of Atazanavir Capsules in the Treatment of HIV in Patients Ages 6 - 18 Years

Condition: HIV, Pediatric

NCT ID: NCT01691794

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01102972

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Condition: HIV Infections

NCT ID: NCT00084136

Comparative Study of Three NNRTI-Sparing HAART Regimens

Condition: HIV Infection

NCT ID: NCT00811954

Switch to Unboosted Atazanavir With Tenofovir Study

Condition: HIV Infection

NCT ID: NCT01351740

Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects

Condition: HIV Infection

NCT ID: NCT00096746

Genetics and HIV-1 Protease Inhibitors

Condition: HIV

NCT ID: NCT01388543

A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine

Condition: HIV Infections

NCT ID: NCT00013897

Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)

Condition: HIV Infections

NCT ID: NCT01138267

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

Condition: HIV Infections

NCT ID: NCT00028301

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

Condition: HIV Infections

NCT ID: NCT00362726

Metabolic Effects of Switching Kaletra to Boosted Reyataz

Condition: HIV Infections

NCT ID: NCT00413153

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

Condition: HIV Infections

NCT ID: NCT00357604

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

Condition: HIV Infections

NCT ID: NCT00365339

Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

Condition: HIV Infections

NCT ID: NCT00084253

Atazanavir/Ritonavir and Zinc Pharmacokinetic Study

Condition: HIV Infection

NCT ID: NCT01475227

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Condition: HIV Infection

NCT ID: NCT01307488

Atazanavir and Lamivudine for Treatment Simplification

Condition: HIV Infections

NCT ID: NCT00885482

BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes

Condition: HIV Infections

NCT ID: NCT00389402

A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

Condition: HIV Infections

NCT ID: NCT00135343

DDI HV (ATV - Merck)

Condition: HIV Infections

NCT ID: NCT00518297

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

Condition: HIV Infections

NCT ID: NCT00756730

A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study

Condition: HIV Infections

NCT ID: NCT00192608

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

Condition: HIV

NCT ID: NCT01620944

Atazavanir/Ritonavir-based HAART in Children

Condition: HIV

NCT ID: NCT01656109

MARCH Central Nervous System Substudy

Condition: HIV-1 Infection

NCT ID: NCT01637233

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01363011

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Condition: Hepatitis C; HIV Infections

NCT ID: NCT00983853

Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression

Condition: HIV-1 Infection

NCT ID: NCT01511809

Sex, Aging and Antiretroviral Pharmacokinetics

Condition: HIV Infections

NCT ID: NCT00666055

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Condition: Hepatitis C; HIV

NCT ID: NCT01565889

Atazanavir Twice Daily

Condition: HIV Infections; Protease Inhibitor

NCT ID: NCT00357721

Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects

Condition: HIV Infections; Protease Inhibitor

NCT ID: NCT00357188

Drug Interaction Study With Proton Pump Inhibitor

Condition: HIV Infections

NCT ID: NCT00357240

Bioequivalence Study of Atazanavir 300 mg Capsule

Condition: HIV Infections

NCT ID: NCT00393328

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

Condition: HIV

NCT ID: NCT01003990

Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

Condition: HIV Infections

NCT ID: NCT00751153

Atazanavir/Ritonavir Maintenance Therapy

Condition: HIV Infections

NCT ID: NCT00084019

Phase IIB Pilot of Atazanavir + Raltegravir

Condition: HIV

NCT ID: NCT00768989

Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Condition: HIV Infections

NCT ID: NCT00977756

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

Condition: HIV Infections

NCT ID: NCT00491556

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

Condition: HIV-1

NCT ID: NCT01274780

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

Condition: HIV Infections

NCT ID: NCT00135434

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

Condition: HIV Infections

NCT ID: NCT00260078

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

Condition: HIV Infections; Lipodystrophy; Wasting Disease

NCT ID: NCT00028314

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Condition: HIV; Hepatitis C; Liver Fibrosis

NCT ID: NCT01231685

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

Condition: Opioid Dependency; HIV Infections

NCT ID: NCT00877591

Atazanavir/Ritonavir (ATV/RTV) Once a Day (QD) + Raltegravir (RAL) Twice a Day (BID) Stable Switch Study

Condition: HIV, Combination Therapy

NCT ID: NCT01332227

A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen

Condition: HIV Infections

NCT ID: NCT00135447

A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir

Condition: HIV

NCT ID: NCT01255371

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

Condition: HIV-1 Infection

NCT ID: NCT01903031

Treatment De-Intensification and Residual HIV-1 in Youth

Condition: HIV-1; HIV Infections

NCT ID: NCT00867854

Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract

Condition: Women's Health; HIV Infection; Genital Diseases, Female

NCT ID: NCT01456962

MARCH Renal Substudy

Condition: Proteinuria; HIV

NCT ID: NCT01637259

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

Condition: HIV

NCT ID: NCT01404572

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Condition: HIV Infections; Treatment Naive

NCT ID: NCT00851799

Drug Interaction Study

Condition: Antivirals/HIV

NCT ID: NCT00646776

Korean Post-marketing Surveillance for Reyataz®

Condition: HIV-1

NCT ID: NCT01450605

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

Condition: Endothelial Dysfunction

NCT ID: NCT00720590

Comparative Tolerability of Protease Inhibitors

Condition: HIV

NCT ID: NCT01450618

Antiretroviral Therapy and Extreme Weight

Condition: HIV Infection

NCT ID: NCT01805427

Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)

Condition: HIV Infection

NCT ID: NCT00707733

NNRTI/PI Toxicity Switch to Darunavir Study

Condition: HIV

NCT ID: NCT00765154

Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events

Condition: HIV-Infection

NCT ID: NCT01417949

Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients

Condition: HIV Infections; Malaria

NCT ID: NCT00421473

Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin

Condition: HCV Coinfection; HIV-1 Infection

NCT ID: NCT01335529

Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

Condition: HIV Infection

NCT ID: NCT01543035

Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis

Condition: Human Immunodeficiency Virus; Hepatitis C

NCT ID: NCT01289951

Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

Condition: ADHD; HIV

NCT ID: NCT01232361

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition: HIV Infections

NCT ID: NCT00042289

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Condition: HIV; HIV Infections

NCT ID: NCT00966329

Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product

Condition: HIV Infections

NCT ID: NCT00773708

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

Condition: Hepatitis C, Chronic; HIV Infection

NCT ID: NCT01332955

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)

Condition: HIV Infection

NCT ID: NCT00708162

Two Part Study to Study Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Subjects

Condition: Acquired Immune Deficiency Syndrome (AIDS); HIV Infections

NCT ID: NCT01923311

Clinical Trial of CNS-targeted HAART (CIT2)

Condition: HIV Infections

NCT ID: NCT00624195

Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions

Condition: Human Immunodeficiency Virus; Hepatitis B, Chronic; Hepatitis C, Chronic

NCT ID: NCT01908660

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

Condition: HIV-1

NCT ID: NCT00665847

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Condition: HIV-1 Infection

NCT ID: NCT01252940

Telaprevir Open-Label Study in Co-Infected Patients

Condition: Hepatitis C, Chronic

NCT ID: NCT01500616

Unboosted Atazanavir as Initial ART Therapy in China

Condition: Antiretroviral Therapy

NCT ID: NCT01459575